Vistagen Therapeutics, Inc. (VTGN): Submission of Matters to a Vote of Security Holders

Vistagen Therapeutics, Inc. (VTGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies FDA eng

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

Vistagen Therapeutics (VTGN) said its PALISADE-4 Phase 3 trial of fasedienol missed primary/secondary endpoints in 238 patients with social anxiety. Primary SUDS change was -9.5 vs -11.4 for placebo (p=0.427). A post-hoc subgroup with very severe social anxiety (n=123) showed nominal benefit (p=0.036). Company plans FDA talks on a revised registrational strategy and said cash of $45.4M funds operations into 2027.

Vistagen Therapeutics, Inc. (VTGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 vtgn-20260615xex991.htm EX-99.1 Document Exhibit 99.1 Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline res

CoreWeave (CRWV) shares dropped nearly 5% to below $80 after announcing a $3 billion convertible debt offering and a potential $2.92 billion equity raise to fund infrastructure expansion. The company aims to use proceeds for growth and to offset shareholder dilution, but the financing plans highlight its capital-intensive expansion and dependence on external funding.

GE Aerospace's CFO addressed durability concerns about the GE9X engine, assuring no delay for Boeing's 777X. The company redesigned the component and began shipping updated engines. GE's stock is trading at $313.47, 15.6% above its GF Value™ of $271.20, indicating modest overvaluation. The company's GF Score™ is 76/100, with strong momentum but mixed insider and guru activity.